Allergan is a global, technology-driven multi-specialty health care company that discovers, develops and commercializes innovative pharmaceuticals, biologics and medical devices that enable people to live life to its greatest potential.
The flagship franchises under the company’s pharmaceutical business portfolio include medical aesthetics, neurosciences, medical dermatology and eye care.
In 2006, besides adding breast aesthetics and dermal filler products to its business portfolio, Allergan also gained a leading product portfolio in obesity intervention that offers minimally invasive devices to help patients achieve sustained weight loss and reduce health risks associated with obesity.
Allergan is committed to enabling patients to reach a natural healthy weight and to live an active lifestyle. Over the last 50 years, obesity has been increasing at an alarming rate. In the United States alone, obesity affects more than 60 million individuals1 and is considered the second leading cause of preventable death.2 Worldwide, approximately 1.6 billion adults are overweight, and it is estimated that obesity affects at least 400 million adults.3
Allergan has joined the effort to fight the growing obesity epidemic with a portfolio of innovative medical devices to help achieve and support sustained weight loss, reduce health risks associated with obesity and help patients realize their goals for healthy living and wellness.
References:
- NIH, 2005; Merrill Lynch, May 2006; Monitor Group
- American Obesity Association. AOA Fact Sheets. Available at http://www.obesity.org/subs/fastfacts/obesity_US.shtml. Accessed January 18, 2007
- World Health Organization, 2005.